Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 67 full-time employees. The company went IPO on 2021-03-26. The firm is focused on the discovery, development and commercialization of treatments for severe, rare neuromuscular and cardiac disorders. The company has built its muscle-focused drug discovery platform. Its platform measures integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, is an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies. EDG-5506 is advancing in multiple clinical trials in individuals with Duchenne, Becker and Limb Girdle 2i muscular dystrophies, and McArdles disease. The firm is also advancing EDG-7500, which is a sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development.